Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 3319-3528

  Frias, Iúri ^a   Neves, Ana Rute ^a   Pinheiro, Marina ^a   Reis, Salette ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

EGCG; Lipid nanoparticles; Nanoparticles; Nutraceuticals; Supplementation

Indexed keywords

EPIGALLOCATECHIN GALLATE; LIPID; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; CATECHIN; DRUG CARRIER; NANOPARTICLE; TEA;

ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG STORAGE; HUMAN; HUMAN CELL; INTESTINE FLUID; NANOENCAPSULATION; PARTICLE SIZE; SIMULATION; STOMACH JUICE; ANALOGS AND DERIVATIVES; CHEMISTRY; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; TEA;

ADMINISTRATION, ORAL; CATECHIN; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; LIPIDS; NANOPARTICLES; TEA;

EID: 84994474541     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S109589     Document Type: Article

References (22)

1. Zhang J, Nie S, Wang S. Nanoencapsulation enhances epigallocatechin-3-gallate stability and its antiatherogenic bioactivities in macrophages. J Agric Food Chem. 2013;61(38):9200-9209.
2. Fangueiro JF, Andreani T, Fernandes L, et al. Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation. Colloids Surf B Biointerfaces. 2014;123: 452-460.
3. Leu JG, Chen SA, Chen HM, et al. The effects of gold nanoparticles in wound healing with antioxidant epigallocatechin gallate and α-lipoic acid. Nanomedicine. 2012;8(5):767-775.
4. Smith A, Giunta B, Bickford PC, Fountain M, Tan J, Shytle RD. Nanolipidic particles improve the bioavailability and α-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer’s disease. Int J Pharm. 2010;389(1-2):207-212.
5. Wang D, Taylor EW, Wang Y, Wan X, Zhang J. Encapsulated nanoepigallocatechin-3-gallate and elemental selenium nanoparticles as paradigms for nanochemoprevention. Int J Nanomedicine. 2012;7:1711-1721.
6. Doktorovova S, Souto EB, Silva AM. Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers-a systematic review of in vitro data. Eur J Pharm Biopharm. 2014;87(1):1-18.
7. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(Suppl 1):S131-S155.
8. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
9. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 2004;113(1-3):151-170.
10. Neves AR, Lucio M, Martins S, Lima JL, Reis S. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int J Nanomedicine. 2013;8:177-187.
11. Danhier F, Lecouturier N, Vroman B, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release. 2009;133(1):11-17.
12. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun. 1991;175(3):880-885.
13. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev. 2001;46(1-3):27-43.
14. Shah P, Jogani V, Bagchi T, Misra A. Role of Caco-2 cell monolayers in prediction of intestinal drug absorption. Biotechnol Prog. 2006;22(1):186-198.
15. Corti G, Maestrelli F, Cirri M, Zerrouk N, Mura P. Development and evaluation of an in vitro method for prediction of human drug absorption II. Demonstration of the method suitability. Eur J Pharm Sci. 2006;27(4):354-362.
16. Müller H, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3-19.
17. Sun Y, Hung WC, Chen FY, Lee CC, Huang HW. Interaction of tea catechin (-)-epigallocatechin gallate with lipid bilayers. Biophys J. 2009;96(3):1026-1035.
18. Smith TJ. Green Tea Polyphenols in drug discovery-a success or failure? Expert Opin Drug Discov. 2011;6(6):589-595.
19. Shahidi H. Nutraceuticals, functional foods and dietary supplements in health and disease. J Food Drug Anal. 2012;20:226-230.
20. Mereles D, Hunstein W. Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises? Int J Mol Sci. 2011;12(9):5592-5603.
21. Yang CS, Wang H. Cancer therapy combination: green tea and a phosphodiesterase 5 inhibitor? J Clin Invest. 2013;123(2):556-558.
22. Feng W, Hwang HS, Kryshtal DO, et al. Coordinated regulation of murine cardiomyocyte contractility by nanomolar (-)-epigallocatechin-3-gallate, the major green tea catechin. Mol Pharmacol. 2012;82(5):993-1000.